Staphylococcal Scalded Skin Syndrome
This document is only valid for the day on which it is accessed. Please read our disclaimer.
Certain strains of Staphylococcus aureus produce exfoliative toxins. In young infants, and in those with renal impairment, these can accumulate and result in widespread exfoliation of the skin known as Staphylococcal scalded skin syndrome (SSSS).
The initial infection is often minor or undetected.
Prodrome - malaise, irritability, fever, severe skin tenderness.
Erythema usually begins on the head and spreads, particularly involving the skin folds. The skin is fragile and the superficial layers shear off like wet tissue paper with minor pressure (Nikolsky's sign). During this time the infant is at risk of significant fluid loss though the skin, secondary infection and may experience severe pain as with a burn.
After several days the skin desquamates and then heals without scarring. Children are usually able to be discharged home within 5-10 days when no further skin loss is occurring and they are free of pain.
Children with SSSS should be admitted for appropriate fluid administration & monitoring, antibiotic and pain management.
IV, NG or oral fluids should be administered as needed to provide to maintenance requirements and allow for excess losses through the skin. Close attention should be paid to urine output and weight.
Swabs should be taken from areas of suspected infection. Anti-staphylococcal antibiotics (e.g. flucloxacillin) should be administered. It is unusual for these infants to have septicaemia. Caregivers should be asked about skin infections and be swabbed and treated as necessary to eradicate carriers of toxin-releasing Staph.
Regular analgesia should be administered to maintain the infant in a comfortable state. This may include paracetamol, oral opiates or opiate infusions.
Some infants require admission to intensive care for fluid and analgesia management.
Nursing protocol for SSSS
|Nose, throat and skin swabs for culture and antibiotic sensitivities, include a specific request for an MRSA screen||For early detection of infection|
|Baseline temperature, pulse, respiratory rate and blood pressure, increase frequency as indicated||To obtain the normal range and detect deterioration of condition|
|Height and weight||To assess fluid loss, monitor weight loss and calculate drug doses|
|Assess skin and record||To assess extent of condition and monitor progress|
|Daily bathing/washes; dependent on mobility and fragility of the skin||To clean the skin|
|Use an oily emollient in the water||To prevent dryness|
|Use a soap substitute such as aqueous cream or emulsifying ointment||Normal soap too astringent|
|Dress denuded areas with Vaseline Gauze soaked liberally in a 50:50 mixture of white soft paraffin/liquid paraffin. These are changed every 12-24hr||For comfort, to promote healing and to protect denuded areas from infection and further trauma|
|Secure with a loose tubigauze suit if the patient is moving||To keep dressings in situ|
|Apply the 50:50 paraffin mix to all exposed areas, in particular the face and napkin area||To protect these areas and prevent further trauma|
|As the dressings dry out, reapply the 50:50 paraffin mix to the Vaseline gauze||To maximize effectiveness of dressings|
|Eyes: at least 4-hourly eye care in the acute period; apply eye ointment/drops as prescribed||To prevent damage, infection and long-term complications|
|Mouth: 2-hourly mouth care if limited oral intake and in the presence of mucosal and lip involvement||To prevent and/or improve mucosal and lip involvement|
|Pressure area: nurse on a pressure-relieving mattress, monitor pressure areas and position patient appropriately||To relieve pressure on the skin and alleviate pain|
|Fluid and electrolyte balance|
|Administer IV replacement fluid as prescribed||To correct fluid, electrolyte and protein loss and prevent dehydration, renal failure and shock|
|Secure cannula with non-adhesive tape/dressing and bandage well. Tape should be left in place until the active process has subsided.||Adhesive tapes/band-aid plasters will damage fragile skin|
|Careful fluid balance monitoring essential||To ensure correct fluid balance and to observe for urinary retention|
|Consider urinary catheter for painful micturition and/or urine retention||To normalise urine output and reduce pain on micturition|
|Encourage/initiate enteral feeding||To prevent weight loss, protein loss and promote wound healing|
|If a nasogastric tube is required, secure with a tubular bandage or non-adhesive tape||Adhesive tape will damage fragile skin|
|Involve dietician for assessment and guidance||To ensure optimum dietary intake|
|Ensure adequate analgesia is administered, consider i.v. analgesics with extensive skin involvement||To ensure child is pain free, extensive skin loss causes high levels of pain that may be difficult to control with oral analgesics alone|
|Minimal handling||To prevent pain and damage to the skin|
|Provide constant environmental temperature where possible (30-32° is optimum)||Temperature regulation is compromised due to extensive skin loss|
|Monitor core temperature closely||Skin temperature is unreliable; at risk of hypothermia because of excess heat loss|
|Nurse under strict infectious and protective precautions in a cubicle||To protect against further sepsis|
|Give practical and emotional support to the child and family||Child and family may experience high levels of distress|
|Teach the parents/carer the skin care regimen to be continued at home||To sustain recovery|
Textbook of Pediatric Dermatology, 2nd edition, Blackwell Science, 2006. Editors: JI Harper, A Oranje, N Prose.
Did you find this information helpful?
- Date last published: 23 January 2017
- Document type: Clinical Guideline
- Services responsible: Paediatric Dermatology
- Author(s): Diana Purvis
- Owner: Diana Purvis
- Editor: Greg Williams
- Review frequency: 2 years
SIGN UP TO RECEIVE GUIDELINE UPDATES
Subscribe below if you want us to let you know about new or updated guidelines
More From Starship
We welcome your involvement. Find out what guidelines are currently in development or under review. Find out more...
Read about the governance process around the Starship Clinical Guidelines and how to format guidelines in development.